14 years ago

Lumora Secures £1.5M in Series B Funding

  • Lumora Ltd, a UK-based molecular diagnostics company, raised £1.5m in Series B funding led by Catapult Venture Managers with participation from Tate & Lyle Ventures LP to accelerate its entry into the clinical molecular diagnostic market.

      • ProblemHealthcare

      "Current methods of molecular diagnostics are slow, expensive, and often inaccurate, leading to misdiagnosis and delayed treatment, particularly in the developing world."

      Solution

      "Lumora's BART Technology platform allows for faster, more accurate, and cost-effective molecular diagnostics, enabling quicker and more effective treatment for a range of conditions, especially in resource-limited settings."

      Covered on